drugset / Trial / NCT04599452
NK Cell Therapy Recurrent/Refractory Elderly AML
NaSingle-groupOpen-labelTreatment
Summary
The aim of this investigation was to assess safety and efficacy of allogenic NK cells therapy for recurrent refractory elderly AML.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2023-12-30
- Completion
- 2023-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allogeneic NK cell | Cell therapy | 1e+07 cells/kg | — |
| Subject | Allogeneic NK cell | Cell therapy | 3e+07 cells/kg | — |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | — |
| Background | G-CSF | Unknown | 150 ug | — |